Hubbard K P, Daugherty K, Ajani J A, Pazdur R, Levin B, Abbruzzese J L
Section of Gastrointestinal Oncology and Digestive Diseases, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Invest New Drugs. 1992 Apr;10(1):39-42. doi: 10.1007/BF01275479.
A total of 15 patients with measurable advanced colorectal adenocarcinoma were prospectively treated with fazarabine (Ara-AC), reconstituted in dimethyl sulfoxide, and administered at a starting dose of 48 mg/m2/day as a continuous intravenous infusion for three days. The dose was repeated every 21 days and dose escalations or reductions were made on the basis of toxicities encountered in the preceding course. No patient achieved either a complete or partial response. Major toxicities encountered were granulocytopenia, thrombocytopenia, nausea, vomiting, anemia, and headache. All toxicities were reversible upon discontinuation of the drug and no life-threatening toxicities occurred. These data indicate that further clinical trials in colorectal carcinoma with this agent and schedule of administration are not warranted.
总共15例可测量的晚期结肠直肠癌患者接受了法扎拉滨（Ara-AC）的前瞻性治疗，该药物用二甲基亚砜复溶，起始剂量为48mg/m²/天，连续静脉输注三天。每21天重复给药一次，并根据前一疗程出现的毒性进行剂量递增或递减。没有患者达到完全缓解或部分缓解。遇到的主要毒性包括粒细胞减少、血小板减少、恶心、呕吐、贫血和头痛。所有毒性在停药后均可逆转，未发生危及生命的毒性。这些数据表明，不建议使用该药物及给药方案对结直肠癌进行进一步的临床试验。
